SCHEMBL1010686

SCHEMBL1010686

CC(C(=O)O)c1c(Cl)nc(Cc2ccc(NC(=O)Nc3ccccc3)cc2)nc1N(C)CC(=O)NC1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 2/20 0.39
EPHX1 P07099 5/20 0.38
RAB9A P51151 5/20 0.38
EPHX2 P34913 3/20 0.38
NPC1 O15118 3/20 0.37
TP53 P04637 2/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
GAA P10253 1/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP2C19 P33261 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1010089 0.88 GAA (0.39) HPGDLMNAEPHX1RAB9AEPHX2
SCHEMBL1011123 0.87 GAA (0.38) SMN1; SMN2LMNAEPHX1EPHX2GAA
SCHEMBL2003191 0.85 TBXA2R (0.43) SMN1; SMN2HPGDLMNAEPHX1RAB9A
SCHEMBL1010949 0.83 SMN1; SMN2 (0.38) SMN1; SMN2HPGDLMNAEPHX1RAB9A
SCHEMBL1652427 0.80 TBXA2R (0.40) LMNAEPHX1RAB9AEPHX2NPC1
SCHEMBL5961320 0.79 EPHX1 (0.41) SMN1; SMN2HPGDLMNAEPHX1RAB9A
SCHEMBL2005214 0.79 PTGDR2 (0.43) HPGDEPHX1RAB9ANPC1ALDH1A1
SCHEMBL8737850 0.79 PTGDR2 (0.43) SMN1; SMN2HPGDLMNAEPHX1RAB9A
SCHEMBL1652114 0.78 EPHX1 (0.42) SMN1; SMN2EPHX1RAB9AEPHX2NPC1
SCHEMBL2007358 0.78 PTGDR2 (0.51) SMN1; SMN2HPGDLMNARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960393-B2 Pyrimidine derivatives useful for the treatment of diseases mediated by CRTH2 ACTIMIS PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
EP-1633726-B1 PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES MEDIATED BY CRTH2 ACTIMIS PHARMACEUTICALS INC (US) 2011-01-05 EP disclosed